- RobertPhillips900   Nov 01, 2016 at 06:55: PM
RobertPhillips900
new user
Gilead Sciences believes it is executing well in the area of Hepatitis C. The market share is staying strong. The company is ensuring access while preserving the value of its Hepatitis C drugs.The company is also executing on the new versions coming to the market.